Lukacinco 4mg medicine powder in Ha Nam prevent and treat chronic bronchial asthma (30 packs)

Dosage form 30 package box
Specifications Montelukast

Ingredient

Composition information	Content
Montelukast	4mg

Uses

indications

Lukacinco drugs are indicated in the following cases:

Montelukast is appointed for older and 6 -month -old patients to prevent and treat chronic bronchial asthma, including preventing both day and night asthma symptoms, treating aspirin sensitive asthma and preventing bronchospasm. Children 2 years old and older, allergic rhinitis all year round for adults and children 6 months and older).

to treat asthma, need to take medicine in the evening. Leukotrien

ATC code: R03D C03

Mechanism of action:

Cysteinyl Leukotrien (LTC 4, Ltd 4, LTE 4) are strong inflammatory factors released from mast cells and eosinophilia. Intermediate substances that cause inflammation associated with Leukotrien cysteinyl receptors (CYSLT) are found in human respiratory tract and cause inflammatory reactions in the respiratory tract, including bronchospasm, mucus secretion, vascular permeability and dynamic increase of eosinophilia.

Montelukast is used with a high selective oral route for CYSLT 1 receptor. In clinical studies, Montelukast inhibits bronchospasm when used in low doses. The bronchodilator effect is observed within 2 hours after drinking. The effect of bronchodilator acts by a substance B is related to Montelukast. Montelukast treatment inhibits bronchospasm at an early and final stage due to Nguyen resistance. Montelukast compared to the placebo, reducing peripheral blood cells in adults and children. In a separate study, Montelukast treatment significantly reduces eosinophilia in the airway, controls clinical asthma symptoms.

Pharmacokinetics

absorption

Montelukast is quickly absorbed after drinking. CMAX concentration in plasma is achieved after 2 hours in children when they are hungry. Maximum maximum cmax is 66%.

In children from 2 months to 6 years old CMAX concentration achieved after 2 hours taken 2 times higher in adults using 10 mg tablets. Taking medicine with apple sauce or drinking with a different meal is clinically significant when using the drug when hungry.

Distribution

Montelukast binds 99% of plasma proteins. The average distribution of Montelukast's distribution is about 8 - 11 liters. Research in mice with Montelukast has radioactive attachment shows that there is a very small amount of brain barrier. In addition, the drug concentration is at least after 24 hours of drug use.

Metabolism

Montelukast is rapidly metabolized, with research at the dose of treatment, the concentration of metabolites is not detected in plasma in both adults and children.

CYP2C8 is the main enzyme in Montelukast's metabolism. In addition, CYP3A4 and CYP2C9 can contribute partly to the metabolic process. However, iTraconazole a CYP3A4 inhibitor shows that there is no change in Montelukast's pharmacokinetics parameters in healthy people taking the dose of 10 mg Montelukast every day. Based on the results of in vitro research in human liver microsome, the Montelukast concentration in plasma is not inhibited by cytochrom P450 3A4, 2C9, 1A2, 2A6, 2C19 or 2D6. Therefore, the effectiveness of the metabolites of Montelukast is negligible.

Elimination

Montelukast's clearance in plasma is 45 ml/minute in healthy adults. After taking Montelukast with radiation, 86% of the drug is recovered after 5 days, 2% are eliminated through the urine.

Most Montelukast and its metabolites are eliminated through the bile.

No need to adjust the dose in patients with renal failure, patients with mild to medium liver failure.

There is no sufficient dynamic research data in patients with severe liver failure with Child - Pugh> 9.

With high doses Montelukast used 20-60 times the recommended dose, there was a decrease in theophyllin concentration in plasma, not seeing this effect at the recommended dose of 10 mg x 1 time/day.

Before taking Lukacinco 4mg medicine powder in Ha Nam prevent and treat chronic bronchial asthma (30 packs)

How to use

Powdered powder mixed with oral fluid. Products must be intact until use.

After opening the drug package, it should be used for 15 minutes. If mixed with food, do not keep the next use.

To treat asthma, need to take medicine in the evening.

With allergic rhinitis, the drug time depends on the needs of each object.

Dosage

recommended dose:

Children from 6 months to 5 years old have asthma and/or allergic rhinitis: 4 mg/day.

Children from 6 years old to 14 years old have asthma and/or allergic rhinitis: 4 - 8 mg/day (depending on the actual situation of children).

Adults and children over 15 years old have asthma and/or allergic rhinitis: 8mg/day (depending on the situation of the patient can adjust the dose).

Children need to be evaluated for the effectiveness of treatment after 2-4 weeks of drug treatment, stop use if not responded to treatment.

Do not recommend used for children under 6 months old.

Products used for children under the supervision of adults.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?

Symptoms of overdose reactions such as abdominal pain, drowsiness, headache, vomiting, epilepsy.

Need to stop the drug and go to the nearest medical facility when there are overdose symptoms.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What do do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using the drug, there are common unwanted effects (ADR) such as:

Infection and infection:

Very common: upper respiratory tract infections.

Rare: Increasing bleeding trend.

immune system disorders:

Uncommon: Hypersensitivity reactions.

Uncommon: Abnormal dreams include nightmares, insomnia, anxiety, agitation including acts of aggression or hostility, depression, discomfort, restlessness, tremor.

Less: dizziness, drowsiness, drowsiness.

Arrhythmia:

Rare: Brushing the chest.

Inexplicable: Nonflathing in the lungs.

Very rare: angina.

Common: diarrhea, nausea, vomiting

Common: Alt concentration, serum AST increased.

Very rare: Hepatitis.

Common: rash.

Less: joint pain, muscle pain including muscle cramps.

General disorder:

Common: high fever.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Lukacinco drug is contraindicated in the following cases:

Hypersensitivity to any ingredients of the drug.

Caution when using drugs

Diagnosis of chronic asthma in children from 6 months - 2 years old should be done by pediatrician or pulmonary specialist.

Patients should not take oral medication in the treatment of acute asthma attacks. If there is a manifestation of acute bronchial asthma attacks, use a short -effect inhalation form B. It is necessary to consult a doctor if the patient is constantly using the ownership of the B -shipping effect.

Montelukast should not suddenly replace inhaled or drinking corticosteroids.

There is no enough data to prove that it can reduce corticosteroids when used simultaneously Montelukast.

In case of body hyperpigmentation, sometimes clinical manifestations of vascular inflammation are similar to Churg - Strauss syndrome, which is often treated with systemic corticosteroids. These cases are involved in reduced dosage of systemic corticosteroids.

Be cautious when used simultaneously with aspirin and other anti -inflammatory drugs NSAID.

Use drugs for women during pregnancy and lactation

Pregnancy

Animal research data shows no defects for the fetus. However, research data on humans is limited. Only use for pregnant women when assessing the benefits of the drug is much higher than the risk.

Breastfeeding period

Research on mice shows that the drug is excreted through milk. There is no sufficient research data on breastfeeding women. It is necessary to consider the benefits of use for breastfeeding women, only used when necessary.

The effect of the drug on the ability to drive and operate machinery

The drug does not affect the ability to drive and operate machinery, but there are also reports on dizziness or drowsiness when using the drug.

Drug interaction

Montelukast is used in prevention and treatment of asthma.

Montelukast's plasma (AUC) concentration decreases by about 40% in patients with phenobarbital. Because Montelukast is metabolized by CYP 3A4, 2C8, and 2C9, should be cautious, especially in children, when Montelukast is used with CYP 3A4, 2C8, and 2C9 induction drugs, such as phenytoin, phenobarbital and rifampicin.

In vitro studies show that Montelukast is a strong inhibitor of CYP 2C8. However, data from a clinical interactive study between Montelukast and Rosiglitazon (CYP 2C8 main metabolites) shows that Montelukast does not inhibit CYP 2C8 in Vivo. Therefore, Montelukast will not change the meaning of the transformation of pharmaceutical products metabolized by this enzyme (for example Paclitaxel, Rosiglitazon and Repaglinid).

In vitro studies show that Montelukast inhibits CYP 2C8, negligible inhibitors are 2C9 and 3A4. In the study of clinical interaction between Montelukast and Gemfibrozil (CYP 2C8 and 2C9 inhibitors), Gemfibrozil increases the concentration of Montelukast 4.4 times. No need to adjust the dose of Montelukast when used with Gemfibrozil or strong CYP 2C8 inhibitors, but the doctor should know about the possibility of adverse side effects.

Based on in vitro data, does not interact with important drugs shown clinically with weak inhibitors CYP 2C8 (such as trimethoprim). Simultaneous use of Montelukast with Itraconazole - a strong inhibitor of CYP 3A4, does not significantly increase the level of Montelukast body.

Storage

Leave a cool place, avoid light, temperature below 30⁰C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.